TABLE 2.

mtDNA in different tissues after diverse NRTI treatmentsa

Treatment (dose)mtDNA/nDNA hybridization ratiob
LiverMuscleHeartBrainWAT
None (controls)100100100100100
AZT (100 mg/kg/day)59 ± 8c (15/15)138 ± 11 (14/8)85 ± 7 (14/8)113 ± 19 (14/8)109 ± 11 (14/8)
3TC (50 mg/kg/day)70 ± 8c (16/16)85 ± 9 (14/8)95 ± 5 (13/14)75 ± 11 (13/10)110 ± 15 (14/8)
ddI (66 mg/kg/day)71 ± 10 (15/15)96 ± 10 (14/8)142 ± 16c (13/15)91 ± 15 (15/13)85 ± 14 (14/8)
d4T (13.5 mg/kg/day)68 ± 7c (15/15)93 ± 8 (13/12)78 ± 6 (10/10)93 ± 16 (15/10)90 ± 16 (15/10)
ddC (0.36 mg/kg/day)80 ± 13 (15/13)77 ± 6 (9/7)89 ± 5 (15/10)72 ± 8 (15/10)89 ± 15 (15/10)
AZT-3TC83 ± 12 (12/14)76 ± 10 (12/14)75 ± 5 (12/14)69 ± 12 (12/10)118 ± 4c (12/10)
d4T-3TC97 ± 5 (10/10)134 ± 10 (8/8)99 ± 5 (10/10)112 ± 4 (10/10)133 ± 8c (8/8)
d4T-ddI99 ± 4 (12/12)142 ± 11 (8/8)89 ± 8 (13/13)100 ± 7 (13/13)86 ± 6 (8/8)
  • a Mice were treated or not with the different analogues for 2 weeks, and the mtDNA/nDNA hybridization ratios were determined as described in Materials and Methods.

  • b The mtDNA/nDNA hybridization ratio in treated mice (mean ± SEM) was expressed as the percentage of the mean mtDNA/nDNA hybridization ratio in the corresponding control mice. The numbers of mice in the control group/treated group are indicated within parentheses.

  • c The value is significantly different from the value for the corresponding control at a P of <0.05.